NCT06765980View on ClinicalTrials.gov

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 28, 2025

Primary Completion Date

December 15, 2027

Study Completion Date

December 15, 2027

Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
GENETIC

VV-14295

VV-14295 will be administered as a single suprachoroidal injection.

Trial Locations (1)

Unknown

RECRUITING

Kriya Clinical Study Site, Christchurch

Sponsors
All Listed Sponsors
lead

Kriya Therapeutics, Inc.

INDUSTRY

NCT06765980 - A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter